Abstract
1 min readACP Journal Club21 May 2013Prednisolone plus chlorambucil preserved renal function in membranous nephropathyGiuseppe Remuzzi, MD, FRCP, Piero Ruggenenti, MDGiuseppe Remuzzi, MD, FRCPIstituto di Ricerche Farmacologiche “Mario Negri” (IRCCS), Bergamo, Italy (G.R., P.R.)Search for more papers by this author, Piero Ruggenenti, MDIstituto di Ricerche Farmacologiche “Mario Negri” (IRCCS), Bergamo, Italy (G.R., P.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-10-201305210-02009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationHowman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013: 381:744-51. https://pubmed.ncbi.nlm.nih.gov/23312808Clinical Impact RatingsNephrology: References1 Perna A, Schieppati A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44:385-401. [PMID: 15332211] Google Scholar2 Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23:1416-25. [PMID: 22822077] Google Scholar3 Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23:1617-30. [PMID: 22859855] Google Scholar Author, Article, and Disclosure InformationAffiliations: Istituto di Ricerche Farmacologiche “Mario Negri” (IRCCS), Bergamo, Italy (G.R., P.R.)This article was published at Annals.org on 7 May 2013. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 May 2013Volume 158, Issue 10Page: JC9KeywordsAntibodiesCreatinineDrugsProteinuriaRenal failureResearch fundingStatinsSteroidsUrine ePublished: 21 May 2013 Issue Published: 21 May 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Discussion(0)
No comments yet. Be the first to comment.